Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • Chapter 8 - The neuropsychiatry ofpsychosis and headache

  • Edited by Mark W. Green, Philip R. Muskin
  • Book:
    The Neuropsychiatry of Headache
    Published online:
    05 March 2013
    Print publication:
    07 March 2013, pp 75-94

  • Summary

    This chapter presents information on the background, diagnosis, clinical features, pathophysiology, forms, and precipitating factors of migraine. There are three major approaches to the treatment of migraines. It is often useful to view a migraine as a low threshold for the development of headache. There are three major approaches to the treatment of migraines: non-medication therapies; acute treatment; preventive treatment. Evidence-based guidelines support the use of cognitive behavior therapy. Most preventive agents for migraine are associated with weight gain, and this side effect, along with memory loss and depression, are the most common reasons for rejecting a particular agent. The Food and Drug Administration (FDA) in the United States issued an alert in 2006 that there would be a life-threatening risk when triptans were used in individuals taking selective serotonin reuptake inhibitors and selective serotonin/norepinephrine inhibitors.